There’s always a better way.


Sarisa is toppling accepted therapeutic limitations that affect many. Our early-stage disruptions are elegant, effective and surprisingly common sense.


ONOCOLOGY – OUTPATIENT – OTC

CANCER



Why take just one path?

Introducing a new class of chemical entities in the war against cancer. Typically, a single molecule is designed to attack a particular cell function needed by cancer cells. However, cancer cells can rapidly adjust their signaling pathways to evade treatments making single agents more vulnerable to treatment evasion. Our unique approach involves the design of a multifunctional molecule that inhibits multiple cancer paths simultaneously, significantly decreasing the likelihood of cancer cells evading treatment.

STATUS
Currently in animal trials

TECH PARTNER
University of Michigan
2 molecules, 2 pathways for
better patient outcomes

Interested in a partnership?


We are always open to conversations about emergent technologies and partnerships in the cause of better care.